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HEMATOLOGIC MALIGNANCIES

special articles
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Oncology, Pakistan Society of Hematology, and
Pakistan Society of Clinical Oncology Joint
Clinical Practice Guideline
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abstract

Diffuse large B-cell lymphoma (DLBCL) is the commonest non-Hodgkin lymphoma encountered by hematopathologists and oncologists. Management guidelines for DLBCL are developed and published by countries
with high income and do not cater for practical challenges faced in resource-constrained settings. This report by
a multidisciplinary panel of experts from Pakistan is on behalf of three major national cancer societies: Society of
Medical Oncology Pakistan, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology. The aim
is to develop a practical and standardized guideline for managing DLBCL in Pakistan, keeping in view local
challenges, which are similar across most of the low- and middle-income countries across the globe. Modiﬁed
Delphi methodology was used to develop consensus guidelines. Guidelines questions were drafted, and
meetings were convened by a steering committee to develop initial recommendations on the basis of local
challenges and review of the literature. A consensus panel reviewed the initial draft recommendations and rated
the guidelines on a ﬁve-point Likert scale; recommendations achieving more than 75% consensus were accepted. Resource grouping initially suggested by Breast Health Global Initiative was applied for resource
stratiﬁcation into basic, limited, and enhanced resource settings. The panel generated consensus ratings for 35
questions of interest and concluded that diagnosis and treatment recommendations in resource-constrained
settings need to be based on available resources and management expertise.
JCO Global Oncol 7:1647-1658. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION

Author affiliations
and support
information (if
applicable) appear at
the end of this
article.
Accepted on
November 10, 2021
and published at
ascopubs.org/journal/
go on December 13,
2021: DOI https://doi.
org/10.1200/GO.21.
00320

Diffuse large B-cell lymphoma (DLBCL) is the commonest non-Hodgkin lymphoma encountered by hematopathologists and oncologists.1,2 A study from Southern
Pakistan reported higher DLBCL frequency (76.4%) and
a younger median age (47.2 years) among newly diagnosed non-Hodgkin lymphoma patients compared
with the Western data.3 Management guidelines for
DLBCL are developed and published by countries with
high income and do not cater for practical challenges
faced in the low-resource countries. This report by a
multidisciplinary panel of experts from Pakistan is on
behalf of three major national cancer societies: Society of
Medical Oncology Pakistan, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology. The
aim is to develop a practical and standardized guideline
for managing DLBCL in Pakistan, keeping in view local

challenges which are similar across most of the low- and
middle-income countries across the globe.
Methodology
The modiﬁed Delphi method was used to generate
consensus statement as recommended by the ASCO.4-6
Literature search was done using PubMed, Embase,
and Web of Science. A steering committee comprising
seven members reviewed the evidence and drafted
initial recommendations after appropriate rationale. A
guideline panel comprising 23 experts was formed,
which rated the guidelines forwarded by the steering
committee on a ﬁve-point Likert scale (strongly agree = 1
point to strongly disagree = 5 points). The ratings were
accepted if consensus ≥ 75% was achieved.
We used the resource grouping suggested by Breast
Health Global Initiative7 and applied this to DLBCL.
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CONTEXT
Key Objective
To develop management guidelines for patients with diffuse large B-cell lymphoma (DLBCL), keeping in view the challenges
faced in resource-limited countries.
Knowledge Generated
This report by a multidisciplinary panel of experts from Pakistan is on behalf of three major national cancer societies, namely Society
of Medical Oncology Pakistan, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology. Consensus guidelines
are generated for diagnosis and management of patients with newly diagnosed and relapsed refractory DLBCL patients.
Relevance
Management guidelines for DLBCL are developed by countries with high income and do not cater for practical challenges
faced in resource-constrained settings. These guidelines are developed keeping in view local challenges, which are similar
across most of the low- and middle-income countries across the globe.

Resource environments were divided into three categories
as per resource availability.
1. Basic: Basic-level services are typically provided in a
single clinical interaction and include patient review by
general practitioners and nononcology fellows.
2. Limited: In addition to basic resources, these are
second-tier services that may involve multiple clinical
interactions. The aim is timely and accurate diagnosis
and to proceed with evidence-based treatments with an
aim to produce major improvements in outcome.

3. Enhanced: In addition to basic and limited resource
level services, enhanced services will provide third-tier
diagnostic and management services required for patients
requiring high-intensity chemotherapy and hematopoietic stem-cell transplant (HSCT) for relapsed-refractory
or high-risk patients.
Detailed distribution of resource environments as per resource
availability is summarized in Table 1. Level of evidence and
grading recommendations8 are listed in Table 2. Summary of
resource-guided interventions is mentioned in Table 3.

TABLE 1. Summary of Resource Distribution for Diagnosis and Management of Diffuse Large B-Cell Lymphoma
Level of Resource
Basic

Clinical Expertise
History
Physical examination

Limited (in addition
to basic resources)

Enhanced (in
addition to basic
and limited)

1. Surgical expertise for
excisional/incisional biopsy
2. Image-guided biopsy
3. Open tissue biopsya

Diagnostic Facilities
Radiology: x-ray, USG

Management Expertise
Initial supportive care and referral to subject
expert

1. Radiology: CT scan, MRIb
1. CHOP/R-CHOP (capacity to handle low
2. Pathology: H&E staining
neutropenic risk , 7 days patients only). For
microscopy, bone marrow
elderly and frail (CVP 6 R, miniCHOP 6 R,
examinationc, limited IHC facility
CEOP 6 R)
(CD20 and CD3)
2. Limited salvage therapy (R 6 ICE, DHAP,
GDP)
3. Others: HbsAg, anti-HCV, anti-HIV,
anti-HbcAb, echocardiography
3. RT
4. IT-MTXd

1. Mediastinoscopya
1. Radiology: PET/CT
2. Pathology: ﬂow cytometrye, full IHC
2. Endoscopic USG guided biopsya
panelf, FISH testing for MYC, BCL2,
3. Endobronchial USG guided biopsya
4. Frozen section facility
BCL6
5. Spinal/neurosurgical procedurea
3. Others: virology (EBV, CMV), fertility
preservation

1.
2.
3.
4.
5.

High-intensity salvage chemotherapy
Infusional regimens
HD-MTX
RT
HSCT

Abbreviations: CEOP, cyclophosphamide, etoposide, vincristine, and prednisolone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone;
CMV, cytomegalovirus; CT, computed tomography; CVP, cyclophosphamide, vincristine, and prednisolone; DHAP, dexamethasone, cytarabine, and cisplatin;
EBER, Epstein-Barr virus-encoded RNA; EBV, Epstein-Barr virus; FISH, ﬂuorescent in situ hybridization; GDP, gemcitabine, dexamethasone, and cisplatin; H&E,
hematoxylin and eosin; HD-MTX, high-dose methotrexate; HSCT, hematopoietic stem-cell transplant; ICE, ifosfamide, carboplatin, and etoposide; IHC,
immunohistochemistry; IPI, international prognostic index; ISH, in situ hybridization; IT, intrathecal; MRI, magnetic resonance imaging; PET, positron emission
tomography; RT, radiotherapy; USG, ultrasonography.
a
In case no accessible tissue available elsewhere.
b
For patients with clinical suspicion of CNS involvement, cord compression if resources permit.
c
For patients with cytopenias and no accessible tissue to biopsy and for staging in absence of PET-CT availability.
d
For patients with high CNS IPI.
e
In cases with leukemic presentation and tissue biopsy inconclusive, for detection of lymphoma cells in pleural ﬂuid, ascitic ﬂuid, or CSF.
f
A certiﬁed hematopathologist or a histopathologist with adequate experience in lymphoma reporting should be available. Complete IHC panel will include
CD45, CD20, CD79a, CD10, BCL2, BCL6, MYC, Ki67, MUM1/IRF4, Cyclin D1, CD5, CD23, and EBER-ISH.
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TABLE 2. Levels of Evidence and Recommendation for Grading
Levels of evidence
I

Evidence from at least one large randomized controlled trial
of good methodologic quality (low potential for bias) or
meta-analyses of well-conducted randomized trials
without heterogeneity

II

Small randomized trials or large randomized trials with a
suspicion of bias (lower methodologic quality) or metaanalyses of such trials or of trials that demonstrated
heterogeneity

III

Prospective cohort studies

IV

Retrospective cohort studies or case-control studies

V

Studies without control group, case reports, and expert
opinions

Grades of
recommendation
A

Strong evidence for efﬁcacy with a substantial clinical
beneﬁt, strongly recommended

B

Strong or moderate evidence for efﬁcacy but with a limited
clinical beneﬁt, generally recommended

C

Insufﬁcient evidence for efﬁcacy or beneﬁt does not
outweigh the risk or the disadvantages (adverse events
and costs), optional

D

Moderate evidence against efﬁcacy or for adverse
outcome, generally not recommended

E

Strong evidence against efﬁcacy or for adverse outcome,
never recommended

GUIDELINE QUESTIONS
1. Diagnosis
1.1. Which essential investigations are required for the
diagnosis of DLBCL-not otherwise speciﬁed (NOS)? A surgical excisional biopsy is widely accepted as the gold
standard for diagnosis of lymphoma (1A).9,10 Core needle
biopsies offer an alternative to excisional or incisional biopsy
but frequently yield small and insufﬁcient sample. Fineneedle aspiration is discouraged (IIA).10,11 For rare cases,
bone marrow (BM) examination or microscopic evaluation of
pleural ﬂuid, ascitic ﬂuid, and cerebrospinal ﬂuid by cell
block histology and conﬁrmation by immunohistochemistry
(IHC; limited/extended) or ﬂow cytometry may be required to
establish the diagnosis. For cases of suspected primary CNS
lymphoma, it is preferable to refer patient to enhanced resource setting for evaluation. Typical morphologic features of
DLBCL include complete effacement of normal architecture
by sheets of atypical large cells. Tumor cells are large and
often resemble centroblasts or immunoblasts. Diagnosis of
primary mediastinal B-cell lymphoma (PMBCL) can be
made with characteristic clinical presentation and morphology, presence of pan-B markers, and additional staining
of CD30, CD200, and TRAF-1.
Once a diagnosis is given, the patient enters treatment
pathway. It is therefore imperative that a correct diagnosis is
made within the available resources.12

Basic resources Timely referral to the subject experts
for diagnosis and management without advising biopsy or
radiologic investigations requiring long waiting times (100%
agreement).
Limited resources Excisional/incisional biopsy is preferred. Morphologic diagnosis of DLBCL needs to be
conﬁrmed by using limited IHC, CD3, and CD20 (IIIB)13;
91% agreement (one suggestion to include Hans algorithm
for all cases, one panelist suggested use of only CD3 and
CD20 for IHC).
Enhanced resources It is recommended to include CD
3, CD 20, CD 10, BCL6, BCL2, C-MYC, CD 30, Ki-67,
MUM1, and cyclin D19 to conﬁrm diagnosis, document cell
of origin (COO), and differentiate DLBCL from doubleexpressor lymphomas (DEL). For characteristic morphology with CD20-negative biopsy, CD138 and leukocyte
common antigen are indicated to rule out plasmablastic
lymphoma. For cases with immunoblastic morphology,
Epstein-Barr virus-encoded RNA in situ hybridization is
recommended; 95% agreement (one panelist suggested
use of CD3 and CD20 IHC only).
1.2. When and how to differentiate DLBC-NOS from other highgrade lymphomas (including high-grade B-cell lymphoma
[HGBCL]-NOS, lymphoblastic lymphoma, Burkitt lymphoma/
leukemia [BL], DEL, and double-hit lymphoma). Basic
resources Not applicable.
Limited resources Not recommended routinely. Selected cases at high risk of MYC positivity (ki67% . 90%,
early relapse or refractory disease, blastoid morphology,
transformation from pre-existing follicular lymphoma) can
be referred to enhanced settings; 90% agreement (two
suggestions not to do testing for HGBCL and BL).
Enhanced resources If feasible, all DLBCL cases need
to be tested for MYC expression and further testing for MYC
and BCL2/BCL6 rearrangements in case of MYC expression. 40% and BCL2 . 50% (strong and cytoplasmic).
Fluorescent in situ hybridization (FISH) break-apart probes
are used, and FISH testing is recommended for all DEL with
germinal center-b phenotype and high Ki67 baseline CNS
involvement and extensive extra nodal disease (IB)10: 90%
agreement (two suggestions not to do testing for HGBCL
and BL).
1.3. What investigations are required for staging and risk
assessment?
1.3.1. What radiologic imaging is required for staging newly
diagnosed DLBCL-NOS? Basic resources Not applicable.
Limited resources Contrast-enhanced computed tomography (CT) scan of the neck, chest, abdomen, and
pelvis is recommended. Positron emission tomography
(PET) scan can divert resources away from treatment, and
careful consideration is required when advising PET-CT
scan: 95% agreement (one panelist suggested use of CT
scan for all cases).
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TABLE 3. Summary of Resource-Guided Interventions in Patients With DLBCL
Level of
Resource
Basic

Clinical Status
New patients

Intervention Type

Intervention Details

Refer for step up care, if clinical suspicion of lymphoma

Consensus Rating by 23 Panelists
(acceptable if > 75%)
100% agreement

Relapsed refractory
Limited

New patients

Diagnosis

1. Excisional/incisional biopsy showing characteristic
91% (one suggestion to include
morphology and conﬁrmation using limited IHC (CD20+,
Hans algorithm for all cases,
CD3–)
one suggestion to use CD20
2. CSF RE, cytology, and MRI brain if CNS involvement
and CD3 only)

Staging

i. Contrast-enhanced CT scan of neck, chest, abdomen,
and pelvis
ii. BME

95% agreement (one suggestion
to have mandatory PET-CT for
all patients)

Treatment limited
stage (nonbulky)

CHOP 6 R* × three cycles + 30 Gy RT OR
CHOP 6 R* × 6 cycles
*Treatment should not be withheld because of
nonaffordability of rituximab, and CHOP chemotherapy
can be given

95% agreement (one suggestion
to use PET-guided approach
Persky et al27)

Treatment limited
stage (bulky)

CHOP 6 R* × six cycles + 30-36 Gy RT
95% agreement (one suggestion
*R-CHOP is preferable (1A); however, for resource-limited
to treat as per COO)
centers, treatment should not be withheld because of
nonaffordability of rituximab, and CHOP chemotherapy
can be given

Advanced stage

95% agreement (one suggestion
CHOP 6 R* × six cycles
to treat as per COO)
*R-CHOP is preferable (1A); however, for resource-limited
centers, treatment should not be withheld because of
nonaffordability of rituximab, and CHOP chemotherapy
can be given

CNS prophylaxis

IT-MTX

95% agreement (one suggestion
to use HD-MTX)

iPET CT

Not recommended

100% agreement

EOT response

CECT scan

100% agreement

Time between EOT
and response
assessment

CT-scan: 4 weeks
PET-CT: 4-8 weeks
RT: 12 weeks

95% agreement (one suggestion
to have PET-CT at 6-8 weeks)

Post-treatment
surveillance
imaging

Not recommended

100% agreement

EOT consolidative
RT

If EOT remission is documented by CT scan, RT to bulky or 100% agreement
isolated skeletal sites as per data from RICOVER-noRTh
and MInT trial. Observe without RT if PET scan is used to
document CR

Maintenance
Relapsed refractory Diagnosis

100% agreement

Salvage
chemotherapy

If transplant eligible, GDP 6 R preferable because of lesser 100% agreement
neutropenia and ease of outpatient administration. Other
options: ICE 6 R, DHAP 6 R, and referral to a transplant
facility if in CR, PR

Failure to ﬁrst-line
salvage

Palliation OR consider referral to centers with enhanced
100% agreement
resources if patient wants to pursue further treatment with
curative intent

HSCT
Pregnancy

Not recommended

Repeat biopsy (excisional/core) to conﬁrm relapse. Apply 100% agreement
extended IHC, EBER ISH, and Cyclin D1 if not done
initially
For presumed CNS relapse on the basis of presentation and
MRI ﬁndings, brain biopsy not recommended

First trimester

Not indicated in CR1, referral to HSCT center in CR2

100% agreement

Pregnancy termination is recommended

100% agreement

(Continued on following page)
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TABLE 3. Summary of Resource-Guided Interventions in Patients With DLBCL (Continued)
Level of
Resource

Clinical Status

Intervention Type

Intervention Details

Consensus Rating by 23 Panelists
(acceptable if > 75%)

Second and third
trimesters

CHOP/R-CHOP can be administered

95% agreement (one suggestion
to delay chemotherapy till
delivery)

Lactation

Avoid breastfeeding if receiving chemotherapy

100% agreement

Richter’s
transformation

R-CHOP
Referral for allogeneic HSCT if resources permit

100% agreement

PMBCL

R-CHOP + RT 30 Gy (for PET-based EOT assessment, RT 95% agreement, one panelist
can be omitted, optional as per physician and patient
suggested CECT scan for
preference, if EOT PET is negative)
response assessment

Testicular
lymphoma

Orchiectomy followed by 6 × R-CHOP + CNS prophylaxis
(IT-MTX) and scrotal irradiation (25-30 Gy)

91% agreement, two panelists
suggested HD-MTX

DEL

6 × R-CHOP + IT/HD-MTX

100% agreement

DHL/THL

Referral to enhanced resource; if referral not possible,
6 × CHOP 6 R and IT-MTX

95% agreement, one panelist
suggested referral for AHSCT in
CR1

Age cutoff

. 60 years

100% agreement

Management

Steroid prephase, G-CSF prophylaxis, dose reduction for
high CIRS-G score, mini-CHOP 6 R, CVP 6 R,
GCVP 6 R

100% agreement

EF cutoff

, 50%

90% agreement (one suggestion
of 45% cutoff, one panelist
mentioned that no cutoff can be
given clearly)

Chemotherapy

R 6 CEOP, CEPP, GCVP, R-Benda

100% agreement

Concurrent CNS
disease

Referral to center with enhanced resources. Alternatively,
R-CHOP-21 with high-dose MTX (≥ 3 g/m2) on day 15

95% agreement, one suggestion
to consider CHOP 6 R and
HD-MTX

Primary CNS
lymphoma

Referral to enhanced resource center. If not possible,
options include WBRT, HDMTX + temozolomide 6 rituximab, HD-MTX

100% agreement

Elderly

Reduced EF

Abbreviations: AHSCT, autologous HSCT; CEOP, cyclophosphamide, etoposide, vincristine, and prednisolone; CHOP, cyclophosphamide, doxorubicin,
vinblastine, and prednisolone; CIRS-G, Cumulative Illness Rating Scale-Geriatric score; COO, cell of origin; CR, complete response; CT, computed tomography;
CVP, cyclophosphamide, vincristine, and prednisolone; DEL, double-expressor lymphoma; DHAP, dexamethasone, cytarabine, and cisplatin; DLBCL, diffuse
large B-cell lymphoma; EBER, Epstein-Barr virus-encoded RNA; EF, ejection fraction; EOT, end of treatment; GCVP, gemcitabine, cyclophosphamide, vincristine,
and prednisolone; GDP, gemcitabine, dexamethasone, and cisplatin; HD, high dose; HSCT, hematopoietic stem-cell transplant; ICE, ifosfamide, carboplatin, and
etoposide; IHC, immunohistochemistry; iPET, interim PET; ISH, in situ hybridization; IT, intrathecal; MRI, magnetic resonance imaging; MTX, methotrexate; PET,
positron emission tomography; PMBCL, primary mediastinal B-cell lymphoma; PR, partial response; RT, radiotherapy; WBRT, whole-brain radiotherapy.

Enhanced resources PET-CT scan if clinical condition
of patient permits (1B)9,10: 95% agreement (1 panelist
suggested use of CT for all cases).

1.3.3. What additional pretreatment investigations are required for intermediate-high international prognostic index
(IPI) patients? Basic resources Not applicable.

1.3.2. What is the role of staging BM examination? Basic
resources Not applicable.

Limited resources Magnetic resonance imaging (MRI)
with gadolinium is recommended for patients with neurologic symptoms or signs. Lumbar puncture is recommended for patients with high IPI, advanced-stage disease
(Ann Arbor III/IV, BM involvement, . 1 extra nodal site,
HGBCL, and those with testicular, breast, and renal involvement [1B]). Intrathecal (IT) chemotherapy needs to be
administered at the same time (1A)10,17: 95% agreement.

Limited resources If CT scan is used for staging, BM
examination is needed10,14: 95% agreement.
Enhanced resources For patients staged using PET-CT
scan, BM testing is not required (2B).10,14 For rare patients
with suspected low-level BM inﬁltration (10%-20%), unexplained cytopenias, and discordant lymphoma with
negative PET-CT evidence of BM involvement, staging BM
examination can be done (2B)15,16: 100% agreement.

Enhanced resources In addition to evaluation as per
limited resources, CSF ﬂow cytometry may be considered
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(2B)18,19: 90% agreement, and two panelists suggested the
use of CSF cytology alone.
2. Treatment of Newly Diagnosed DLBCL
It is recommended to have hematology oncology multidisciplinary team (MDT) meetings and counseling for fertility preservation in all institutions offering enhanced-level care to patients
with lymphoma.20-22 If radiotherapy (RT) is part of consensus
recommendation of MDT, consultation may be sought from the
radiation oncologist before initiation of therapy.23,24

improve on R-CHOP with dose intensiﬁcation and incorporation of novel agents have been largely futile.29-33
Basic resources Not applicable.
Limited resources CHOP 6 R* for six cycles (95%
agreement, and one suggestion to treat as per COO)
*R-CHOP is preferable (1A); however, it is not recommended to withhold treatment because of nonaffordability
of rituximab, and CHOP chemotherapy can be given.

2.1. What is the initial treatment of limited-stage (stage IA or
IIA) DLBCL?

Enhanced resources R-CHOP for six cycles (1A)9,10,34
(95% agreement, and one suggestion to treat as per COO).
RT may be considered for initial bulky disease as per
physician and patient discretion (IIB).

2.1.1. Limited-stage nonbulky (< 7.5 cm). Basic resource
Not applicable.

2.3. What is the optimal CNS prophylaxis for newly diagnosed DLBCL? Basic resources Not applicable.

Limited resources Cyclophosphamide, doxorubicin,
vincristine, and prednisolone (CHOP) 6 rituximab (R)* ×
three cycles + 30 Gy RT OR CHOP 6 R* × six cycles.

Limited resources IT chemotherapy: 100% agreement.35,36

*R-CHOP is preferable (1A); however, it is not recommended to withhold treatment because of nonaffordability
of rituximab, and CHOP chemotherapy can be given25:
95% agreement.
Enhanced resources Options include the following:
i. Disease at sites with low RT morbidity (groin, neck, and
axilla): three cycles of R-CHOP + RT 30 Gy (1B).9,10
ii. For IPI = 0, provide four cycles of R-CHOP followed by
two cycles of rituximab if interim PET (iPET) scan document complete metabolic response (Deauville score 13).26 If IPI . 0 and disease at sites where RT needs to be
avoided, provide six cycles of R-CHOP(1A).10
iii. PET-directed therapy using three cycles of R-CHOP
followed by iPET assessment. If iPET-negative (Deauville score 0-3), one additional R-CHOP without RT and
if iPET-positive (Deauville score 4), an additional cycle of
R-CHOP followed by RT 30 Gy and end-of-treatment
(EOT) PET scan. For the Deauville score of 5, repeat
biopsy is advised27 (95% agreement, and one panelist
suggested PET-directed therapy for all patients).
2.1.2. Limited-stage bulky (‡ 7.5 cm). Basic resource Not
applicable.
Limited resources CHOP 6 R* for six cycles
*R-CHOP is preferable (1A); however, it is not recommended to withhold treatment because of nonaffordability
of rituximab, and CHOP chemotherapy can be given (100%
agreement).
Enhanced resources R-CHOP for six cycles9,10,28: 95%
agreement, and one panelist suggested PET-directed
therapy for all patients. RT may be considered as per
physician and patient discretion keeping in mind the risks
and beneﬁts (IIB).
2.2. What initial treatment is recommended for advancedstage DLBCL? Over the past decade, the attempts to

Enhanced resources IT chemotherapy or high-dose
methotrexate (HD-MTX) as per physician and patient
discretion (95% agreement, and one panelist suggested
use of IT chemotherapy only).37,38 Recent studies by
Puckrin et al35 and Eyre et al36 have called efﬁcacy of HDMTX for CNS prophylaxis into question by documenting
lack of beneﬁt in CNS relapse, overall survival (OS), and
disease-free survival with HD-MTX.
2.4. How to monitor patient after EOT?
2.4.1. What radiologic investigation to choose for EOT
response? If resources permit, PET-CT scan at EOT is
preferred for response assessment. Pretreatment PET-CT is
not essential for documenting EOT response.12
Basic resources Not applicable.
Limited resources CT scan for response assessment
as per Lugano response assessment criteria16: 95%
agreement, and one panelist suggested use of PET-CT.
Enhanced resources PET-CT scan: 95% agreement,
and one panelist suggested the use of CT.
2.4.2. What is the optimal time between EOT and response
assessment? For patients receiving chemotherapy, CT
scan needs to be done after 4 weeks and PET scan 4-8
weeks after treatment: 100% agreement. PET scan is
recommended 12 weeks after RT (III B)39; 100%
agreement.
2.4.3. What post-treatment surveillance is recommended for
patients achieving complete remission at EOT (limited-stage
and advanced-stage disease)? For patients achieving
complete remission after EOT, guideline recommendations
of National Comprehensive Cancer Network (NCCN), British
Committee for Standardization in Hematology, and European
Society of Medical Oncology guidelines do not recommend
routine surveillance scans for stage I/II disease. NCCN
recommends only CT imaging every 6 months for 2 years for
stage III/IV disease. CT scans are preferred over PET-CT.
Basic resources Not applicable.
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Limited resources Surveillance radiologic imaging not
recommended if EOT complete remission is documented
(IB): 100% agreement.

presentation and supportive MRI ﬁndings, repeat brain
biopsy is not recommended as it provides little clinical
beneﬁt and adds to morbidity and mortality.43
Basic resources Not applicable.

Enhanced resources No radiologic imaging for limitedstage DLBCL. CT scan every 6 months for 2 years for
advanced stage may be considered, at physician discretion
(95% agreement, and one panelist suggested no imaging
for advanced stage disease).

Limited resources Repeat biopsy (excisional, core
biopsy; 1A), CT scan for staging (95% agreement).

2.5. What is the role of EOT consolidative RT in patients with
bulky disease? The role of RT following CR (on the basis of
CT scan) was documented by German RICOVER-noRTh
trial,28 where addition of RT improved event-free survival
(HR 2.1, P = .005) and a trend toward improved OS (HR 1.6,
P = .127). However, a recent study by Freeman et al40
documented that for patients with EOT-negative PET scan,
RT can be avoided without increasing relapse risk and
compromising OS in patients with bulky diseases at diagnosis.

3.2. What salvage treatment is to be offered for relapsedrefractory patients? Basic resources Not applicable.

Basic resources Not applicable.
Limited resources If EOT remission is documented by
CT scan, RT to bulky or isolated skeletal sites as per data
from RICOVER-noRTh and MInT trial. Observe without RT if
PET scan is used to document CR40: 100% agreement.
Enhanced resources If EOT remission is documented
by CT scan, RT to bulky or isolated skeletal sites as per data
from RICOVER-noRTh and MInT trial. Observe without RT if
PET scan is used to document CR40: 100% agreement.
2.6. What is the role of iPET-CT assessment in limited-stage
and advanced-stage DLBCL? Basic resources Not applicable.
Limited resources Not recommended; 100% agreement.

Enhanced resources Repeat biopsy (excisional, core
biopsy; 1A), PET-CT (95% agreement, and one suggestion
to use PET-CT only if transplant eligible). Extended IHC,
cyclin D1, and Epstein-Barr virus-encoded RNA in situ
hybridization need to be done.

Limited resources If transplant eligible, gemcitabine,
dexamethasone, and cisplatin (GDP) 6 R preferable because of lesser neutropenia and ease of outpatient administration. Other options include ifosfamide, carboplatin, and
etoposide (ICE) 6 R, dexamethasone, cytarabine, and cisplatin (DHAP) 6 R, and referral to a transplant facility if in CR
or PR (95% agreement, and one suggestion to use ICE 6 R
preferably and use salvage only if transplant eligible).
Enhanced resources ICE 6 R, DHAP 6 R, and
GDP 6 R salvage followed by autologous HSCT (AHSCT)
consolidation if in CR or PR. Rituximab to be included if
disease relapsed after 6 months and rebiopsy shows CD20
expression. For primary refractory DLBCL, rituximab can be
omitted in salvage (NCCN ver 4.2021) (95% agreement,
and one suggestion to use ICE 6 R preferably and use
salvage only if transplant eligible).

Enhanced resources Not recommended: 95% agreement, and one suggestion to use iPET scan.

3.3. What further treatment will you offer to patients not
responding to ﬁrst-line salvage? Basic resources Not
applicable.

2.7. What is the role of maintenance therapy in DLBCL? When
will you offer it? Elderly patients with DLBCL relapsing after
ﬁrst-line chemoimmunotherapy have limited therapeutic
options and poor OS. A phase III randomized REMARC trial
documented that lenalidomide maintenance improved PFS
versus placebo in elderly patients with DLBCL responding
to ﬁrst-line R-CHOP.41,42

Limited resources Option of palliative versus novel
agents needs to be discussed depending on transplant
eligibility and patient resources/wishes. Referral to centers
with enhanced resources if patient wants to pursue further
treatment with curative intent: 95% agreement, and one
panelist suggested palliation for all cases.

Basic resources Not applicable.
Limited resources Not recommended: 100% agreement.
Enhanced resources Lenalidomide maintenance (2B)
for patients age 60-80 years41 as per physician and patient
discretion (86% agreement, and one suggestion to avoid,
one suggestion to use in partial response [PR], and one
suggestion to use in clinical trial).
3. How to Manage Relapsed-Refractory Patients
3.1. What investigations are to be advised for relapsedrefractory patients? The postpredictive value of a PETpositive lesion is low (50%-82%), and a rebiopsy is
strongly recommended before second-line treatment. For
patients with presumed CNS relapse on the basis of

Enhanced resources For patients with available resources and good functional status, options include
polatuzumab + bendamustine + rituximab. Patients with
MYD-88 mutation have shown impressive responses to
ibrutinib. Alternatively , brentuximab vedotin (CD30-positive lymphoma), blinatumomab and tafasiamab can be
considered34: 91% agreement, and two panelists suggested palliation for all cases.
4. What Are Transplant Indications in Patients
With DLBCL?
4.1. Transplant indications in newly diagnosed DLBCL. Basic
resources Not applicable.
Limited resources Not recommended in CR1: 100%
agreement.
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Enhanced resources Not recommended in CR1:
100% agreement.

discouraged for patients receiving chemotherapy in the last
trimester (100% agreement).

4.2. Transplant indications in relapsed-refractory DLBCL. Basic
resources Not applicable.

5.2. What treatment will you offer to patients with Richter’s
transformation? Basic resources Not applicable.

Limited resources Second complete remission (CR2)
and beyond: 95% agreement, and one suggestion to offer
palliation.

Limited resources R-CHOP 21 and if in CR and
transplant eligible, referral for reduced-intensity conditioning
allogeneic HSCT consolidation: 95% agreement, and one
panelist suggested observation after chemotherapy.

Enhanced resources CR2 and beyond. Some cases
can be offered transplant in PR if chemosensitive: 95%
agreement, and one suggestion to offer palliation.
4.3. Transplant indications in DHL, DEL, and HGBCLNOS. Basic resources Not applicable.
Limited resources (100% agreement)
DHL/DEL: Transplant in CR1 is not recommended44 (IIB).
Enhanced resources (100% agreement)
DHL/DEL: Transplant in CR1 is not recommended44 (IIB).
4.4. Till what age will you offer AHSCT to patients with DLBCL
with otherwise good functional status and low hematopoietic
stem-cell transplant comorbidity index score? For patients
age , 65 years with good performance status, Eastern
Cooperative Oncology Group (ECOG) 0-1, and no major
organ dysfunction, AHSCT can be considered: 100%
agreement.
4.5. What are the indications for allogenic HSCT in DLBCL?
Recommended in the following subsets of patients45
(100% agreement):
i. Relapsing after autologous HSCT (IIB)
ii. Those failing to harvest stem cells for autologous
transplant (IIB)
iii. Richter transformation (IIB)
5. Management of Special Circumstances
5.1. How will you manage limited-stage and advanced-stage
DLBCL in pregnancy? Management of lymphoma in pregnancy requires management by MDT. Diagnosis and
staging of lymphoma require investigations with an aim to
minimize radiation exposure to mother. Whole-body MRI, xray chest, and ultrasonography are preferable in this
context as per resource availability.

Enhanced resources R-CHOP 21 and if CR after
chemoimmunotherapy, consolidation with reducedintensity conditioning allogeneic HSCT.48 For patients not
responding to ﬁrst-line R-CHOP, other options include
R-GDP, R-DHAP, and R-ICE. Off-label use of
rituximab + lenalidomide + ibrutinib (RLI), checkpoint inhibitors, and venetoclax: 95% agreement, and one panelist
suggested observation after chemotherapy.
5.3. What treatment will you offer as upfront therapy for
PMBCL. Because of lack of randomized trials, optimal ﬁrstline treatment in patients with PMBCL is unknown. Aviles
et al reported the use of RT as adjuvant treatment in patients with CR after six cycles of R-CHOP and documented
improvement in the PFS and OS with minimal toxicities.49
PET-directed approach to omit RT for EOT PET-negative
patients is supported by recent studies50,51 and currently
being evaluated in the IELSG37 trial. A phase II trial conducted by the National Cancer Institute using DA-EPOCH-R
(dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) without radiation documented a 5-year event-free survival of 93%
among 51 patients.
Limited resources R-CHOP + RT if CT scan is used for
remission assessment. For PET-based EOT assessment,
RT can be omitted (optional as per physician and patient
preference) if EOT PET is negative (41): 95% agreement,
and one panelist suggested CT imaging.
Enhanced resources DA-EPOCH-R preferred. The
other option is R-CHOP 6 RT as per EOT PET response:
95% agreement, and one panelist suggested R-CHOP and
CT imaging.

First trimester Pregnancy termination is recommended. For selected cases with limited-stage disease and
unwilling for termination, watchful waiting till second
trimester46 (100% agreement).

5.4. What treatment will you offer to patients with testicular
lymphoma? Testicular involvement in DLBCL is associated
with increased CNS involvement at diagnosis, increased
risk of CNS relapse, and adverse prognosis.

Second and third trimesters CHOP/R-CHOP can be
administered after ﬁrst trimester. Risk of fetal malformations is not increased; however, risk of preterm birth is
higher.47 Methotrexate needs to be avoided throughout
pregnancy: 95% agreement, and one suggestion to delay
chemotherapy till delivery.

Limited resources Orchiectomy followed by six × RCHOP + CNS prophylaxis (IT-chemotherapy) and scrotal
irradiation (25-30 Gy)52: 91% agreement, and two panelists
suggested HD-MTX.

Delivery and lactation Delivery to be scheduled 2-3
weeks after cycle completion and breastfeeding is

Enhanced resources Orchiectomy followed by six × RCHOP + CNS prophylaxis (IT/HD-MTX) and scrotal irradiation (25-30 Gy)52: 95% agreement, and one panelist
suggest IT chemotherapy.
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5.5. What is the optimal ﬁrst-line treatment for patients with
DEL and DHL? Basic resources Not applicable.
Limited resources DEL: six × R-CHOP + ITchemotherapy
DHL: Referral to enhanced resource setup for intensive
regimens. If referral not possible, it is suggested to give
six × R-CHOP with IT chemotherapy (95% agreement).

Basic resources. Not applicable.
Limited resources. R-cyclophosphamide, etoposide, vincristine, and prednisolone (CEOP); R-cyclophosphamide,
etoposide, procarbazine, and prednisolone (RCEPP); and
RGCVP. Treatment modiﬁcation if EF , 50%; 100%
agreement.

Enhanced resources DEL: six × R-CHOP + IT chemotherapy/HD-MTX

Enhanced resources. R-CEOP, RCEPP, and RGCVP: treatment modiﬁcation if EF , 50% (100% agreement).

DHL: six × DA-EPOCH-R + IT chemotherapy/HD-MTX

5.8. How will you manage patients with concurrent CNS
disease at presentation? Basic resources Not applicable.

(95% agreement, and one panelist suggested R-CHOP and
IT chemotherapy for DHL)
5.6. How to manage elderly patients with DLBCL?
5.6.1. What age limit will you consider for classifying patients as elderly in Pakistani population? Generally, geriatric assessment needs to be done routinely for patients
age . 60 years; 100% agreement.
5.6.2. What factors will you consider in deciding upfront
treatment (curative v palliative)? Use of ECOG alone is not
recommended to decide upfront treatment. Elderly patients
with low Charlson Comorbidity Index (CCI) score and low
Cumulative Illness Rating Scale-Geriatric (CIRS-G) score
are candidates for curative therapy36: 95% agreement, and
one panelist suggested low-intensity treatment for all patients age . 60 years.
5.6.3. How will you approach management of newly diagnosed elderly patients with DLBCL?
i. Consider steroid prephase if ECOG . 2 (2B)
ii. Primary granulocyte colony-stimulating factor prophylaxis for patients age . 65 years or those who are frail
and with signiﬁcant comorbidities (1A)
iii. Dose reduction if high CCI or CIRS-G score
iv. Standard R-CHOP for low CCI and CIRS-G patients
age , 70 years
v. R-mini-CHOP for patients age . 70 years
vi. Alternatives include RLI;53 bendamustine-rituximab;54
R-cyclophosphamide, vincristine, and prednisolone
(CVP); R-gemcitabine, cyclophosphamide, vincristine,
and prednisolone (GCVP)
(95% agreement, and one suggestion to avoid doxorubicin
for patients age . 60 years and use CVP 6 R)
5.7. What treatment will you offer to patients with reduced
ejection fraction (EF)? What cutoff of EF will you consider for
treatment modiﬁcation? The deﬁnition of chemotherapyrelated heart dysfunction is decline in EF of at least 5% to
below 55% with accompanying signs or symptoms of
congestive heart failure, or a decline in EF of at least 10% to
below 55% without accompanying signs or symptoms.55
For patients with cardiac dysfunction, substitution of
doxorubicin with etoposide, gemcitabine, or liposomal
doxorubicin may be considered (IIIC).56

Limited resources Referral to center with enhanced
resources. Alternatively, CHOP-21 6 R with IT chemotherapy and whole-brain radiotherapy (WBRT): 95%
agreement, and one suggestion to consider CHOP 6 R and
HD-MTX.
Enhanced resources Intensive chemoimmunotherapy
(methotrexate, thiotepa, rituximab/R-ICE/HD-MTX + ifosfamide alternating with Ara-C+ thiotepa) followed by autologous HSCT/etoposide and cytarabine consolidation (100%
agreement).
5.9. What treatment plan would you offer for primary CNS
large B-cell lymphoma in ﬁrst line and relapse setting in
young/ﬁt and older/less ﬁt individuals? Newly diagnosed
Limited resources WBRT, HD-MTX + temozolomide 6
rituximab, and HD-MTX + procarbazine + vincristine 6
rituximab (100% agreement).
Enhanced resources Reasonable regimens include
(1) rituximab + HD-MTX + high-dose cytarabine;
(2) rituximab + HD-MTX + temozolomide; (3) HDMTX + Ara-C + thiotepa + rituximab; and (4)
rituximab + HD-MTX + procarbazine + vincristine.57 There
is growing evidence to suggest that the use of AHSCT
consolidation improves survival outcomes. Otherwise,
consolidation with high-dose cytarabine OR WBRT needs
to be considered if AHSCT is not available in patients
age , 60 years (100% agreement).
Relapsed refractory Treatment options for relapsed
refractory PCNS DLBCL are limited, and outcomes are
dismal.
Basic resources Not applicable.
Limited resources WBRT, HD-MTX, high-dose Ara-C
and etoposide, lenalidomide, and temozolomide (combination): 91% agreement, and two panelists suggested
palliation.
Enhanced resources Reasonable regimens include
(1) rituximab + HD-MTX + high-dose cytarabine; (2) highdose cytarabine with etoposide followed by thiotepa-based
AHSCT; (3) ibrutinib; (4) lenalidomide; and (5) immune
checkpoint inhibitors followed by AHSCT if in CR: 91%
agreement, and two panelists suggested palliation.
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